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Abstract
Background: TAS-102 (trifluridine and tipiracil hydrochloride; a novel combination oral nucleoside anti-tumor
agent) has recently received regulatory approval for patients with refractory metastatic colorectal cancer (mCRC).
Internal review of data at a single-institution showed a trend towards better overall survival (OS) for patients who
experienced chemotherapy-induced neutropenia at 1-month (CIN-1-month). To explore this finding further, a
cohort study was designed based on outcome data from three centers in United States and one from Japan.
Methods: CIN-1-month after starting TAS-102 was defined by the Common Terminology Criteria for Adverse Events
(CTCAE), version 4.03 as a neutrophil count decrease of ≥ grade 2 (absolute neutrophil count < 1500/mm3). Patients
had confirmed mCRC that was refractory to standard therapies. Patient demographics and clinical characteristics
were compared between patients with CIN-1-month (CIN-1-month positive) versus those who did not have CIN-1-
month (CIN-1-month negative); with the median progression-free survival (PFS) and OS were calculated using the
Kaplan-Meier method, and differences evaluated using the Log-rank test.
Results: Our cohort study had a total of 149 patients with data regarding their neutrophil assessment at 1-month
mark. Patients who developed ≥ grade 2 CIN-1-month had a both longer PFS (median 3.0 months versus 2.
4 months; Log-rank P-value = 0.01), as well as OS (14.0 versus 5.6 months; Log-rank P-value < 0.0001). Only CIN-1-
month (adjusted HR: 0.21 (95 % CI: 0.11–0.38) and higher baseline CEA levels (adjusted HR: 2.00 (95 % CI: 1.22–3.35)
were noted to be independent predictors of OS. Furthermore, the CIN-1-month was noted to be a statistically
significantly predictor of OS over a wide range of cutoffs.
Conclusions: Our observations are novel and hypothesis generating. Neutropenia after starting TAS-102 was
associated with better prognosis in patients with refractory mCRC. It can be postulated that the dosage of TAS-102
potentially may need to be increased to achieve better outcomes in patients not experiencing any neutropenia.
Further pharmacologic investigations should help elucidate these issues.
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Background
TAS-102 (trifluridine and tipiracil hydrochloride; a novel
combination oral nucleoside anti-tumor agent) was first
approved in Japan in March 2014 and received US Food
and Drug Administration (FDA) approval in September
2015 after an international phase-III clinical trial in pa-
tients with refractory metastatic colon cancer demon-
strated a benefit in overall survival for TAS-102
compared with placebo [1]. Prior to the FDA approval,
patients had access to an expanded access program
(EAP) of TAS-102 at various institutions within United
States. Internal review of outcome data at Mayo Clinic
in patients who were treated through the EAP showed a
trend towards longer progression free survival (PFS) and
overall survival (OS) for patients who were noted to
have neutropenia after one cycle (4 weeks) of therapy.
To explore this finding further, we validated these find-
ings with outcomes data on additional patients who had
received TAS-102 at the Yale Cancer Center, United
States, as well as at the National Cancer Center Hospital
East, Japan, where the drug had been approved in 2014.
Chemotherapy induced neutropenia (CIN) at 1-month
mark [CIN-1-month] after starting TAS-102 was defined
by the Common Terminology Criteria for Adverse Events
(CTCAE), version 4.03 as a neutrophil count decrease
of ≥ grade 2 (absolute neutrophil count < 1500/mm3).
Our hypothesis was that the hematological toxicity
(CIN-1-month) was a predictive marker of outcomes in
patients with refractory metastatic colorectal cancer
through several potential mechanisms (Fig. 1). In fact, in a
recently published preclinical model, trifluridine (TFT;
which is the anti-tumor component of TAS-102) incorpo-
rated itself in the DNA of the colorectal tumor as well as
the DNA of the white blood cell in a dose dependent man-
ner [2]. The highest tolerable TFT concentration was the
one that provided the highest anti-tumor activity, with
hematological toxicity as a potential surrogate marker for
the effectiveness of the drug [2]. If our hypothesis is valid,
patients who do not have chemotherapy induced neutro-
penia should have a higher risk of death. The results would
provide further rationale to these observations. It will fur-
ther elucidate the mechanism of action of the drug respon-
sible for its anti-tumor activity. Furthermore, the clinical




Patients enrolled in the EAP cohort were age 18 years or
older with confirmed metastatic adenocarcinoma of the
colon or rectum, and an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1. Patients
needed to have previously progressed during or within
3 months following the last administration of approved
standard therapies which must have included fluoropyri-
midine, oxaliplatin, irinotecan, bevacizumab or afliber-
cept and cetuximab or panitumumab if RAS wild-type.
Patients who had withdrawn from standard treatment
due to unacceptable toxicity warranting discontinuation
of treatment and precluding retreatment with the same
agent prior to progression of disease were also allowed
to enter the EAP. The detail of the eligibility criteria for
the EAP that was open at 33 different sites within United
States is available at http://clinicaltrials.gov (identifier:
NCT02286492) [4]. For the purpose of this study, our
EAP cohort comprised of patients from three cancer cen-
ters in United States (Mayo Clinic Rochester, Mayo Clinic
Arizona and Yale Cancer Center).
Expanded Access Program (EAP) cohort from United
States
Our ‘EAP cohort’ comprised of patients who were enrolled
through the expanded access program (EAP) of TAS-102
at the Mayo Clinic (Rochester and Arizona sites, United
Fig. 1 Postulated mechanisms between association of chemotherapy-induced neutropenia at 1-month mark (CIN-1-month) and overall survival:
(a) Firstly, one may postulate that patients with a high tumor burden could have a high baseline neutrophil count; making it less likely to
experience CIN-1-month; (b) Secondly, since the drug incorporates into the tumor, for patients with a high tumor burden, it is possible
that that the standard dosage of the drug may not be enough to exert myelotoxicity; and c) Finally, individuals experiencing different degrees of
neutropenia may have different pharmacokinetics of TAS-102 and its metabolites
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States) and the Yale Cancer Center, New Haven, Connecti-
cut, United States between March 04, 2015 and Septem-
ber 30, 2015. Institutional Review Board (IRB) approvals
were obtained from both institutions prior to the initiation
of the EAP, alongside approval from Taiho Pharmaceutical
Co. LTD.
Validation cohort from Japan
Our ‘validation cohort’ included patients with histologi-
cally confirmed colorectal adenocarcinoma who were
treated with TAS-102 in Japan from May 01, 2014 to
September 30, 2015 [5]. The retrospective data from the
validation cohort was collected under an IRB waiver in
accordance with the Japanese Ethical Guidelines for Epi-
demiological Research.
Study design
To answer the question if CIN-1-month affects outcomes
in patients with refractory metastatic colorectal cancer, a
cohort study was performed. All patients were treated
with TAS-102 at a dose of 35 mg/m2 administered orally
twice daily for 5 days a week with 2 days’ rest for 14 days,
followed by a 14-day rest (1 treatment cycle). Patients with
chemotherapy induced neutropenia (CIN) at 1-month
mark [CIN-1-month] after starting TAS-102 as defined by
the Common Terminology Criteria for Adverse Events
(CTCAE), version 4.03 as a neutrophil count decrease
of ≥ grade 2 (absolute neutrophil count < 1500/mm3) were
defined as the CIN-1-month positive group. Patients with-
out CIN-1-month were the reference group (CIN-1-month
negative group). Patients were subsequently assessed for
the different outcomes as described.
Endpoints and assessments
The medical records of patients were retrospectively
reviewed by investigators at the four institutions and
data abstracted for the purposes of this study to gather
data regarding PFS, OS and outcome of their first imaging
computed tomography (CT) scans. PFS was defined as the
interval from the start of TAS-102 treatment to either dis-
ease progression or death. OS was defined as the interval
from the start of TAS-102 treatment to death. For PFS or
OS, the patients were censored at their last follow-up visit
if they were free of disease progression or death, respect-
ively [5]. The median PFS and OS were calculated using
the Kaplan-Meier method, and differences between pa-
tients with and without CIN-1-month were evaluated
using the Log-rank test. Data from both cohorts were
combined for further reporting and analysis. Additionally,
separate subset analyses were also conducted for the end-
points described. Patients with less than 4 weeks (28 days)
of follow up were excluded from the final analysis.
Statistical analysis was performed using JMP®10.0 (2012
SAS Institute Inc.). Laboratory data regarding absolute
neutrophil counts and carcinoembryonic antigen (CEA)
level were also collected if available at baseline and on day
1 of initiation of different cycle visits. Based on the me-
dian, patients were divided into older adults (age >65) and
young adults (age ≤65), high CEA levels (CEA >55 ng/ml)
and low CEA levels (≤55 ng/ml), and high baseline
neutrophil count (> 4300/mm3) and low baseline neutro-
phil count (≤ 4300/mm3). Sensitivity analyses were also
conducted based on different cutoffs of neutrophil count
at 1-month mark to assess the relationship between
hematologic toxicity and overall survival.
Results
Patients
The EAP cohort had a total of 83 patients (49 patients
from the two Mayo Clinic sites and 34 from the Yale
Cancer Center). The validation cohort from Japan had 92
patients. Thus, the study included a total of 175 individ-
uals. Excluding patients with less than 4 weeks (28 days) of
follow up (18 patients; 10 %), our final cohort had a total of
157 patients. Data on neutrophil counts at the 4-week
mark were available in 149 patients, 69 (46 %) of which
experienced neutropenia (CIN-1-month positive) and 80
(54 %) who did not (CIN-1-month negative).
Comparison between EAP and validation cohorts
We compared baseline characteristics and outcome data
between the EAP cohort from United States and the valid-
ation cohort from Japan to see if there were any differ-
ences that might be explained by patients from different
origins. Patient in the EAP cohort were noted to be youn-
ger (median age 61 years versus 65 years; P-value = 0.08).
No statistically significant differences were noted between
the two cohorts in the demographic characteristics or out-
comes (data not shown). Therefore, further analyses re-
ported in the paper are on the 2 cohorts combined.
Efficacy
A total of 144 patients had their first staging imaging
scans (~ after 2 cycles of therapy) available for review.
At first evaluation, 84 (58 %) patients had progressive
disease (PD), 55 (38 %) patients had stable disease (SD)
and 5 (4 %) patients had a partial response (PR) to TAS-
102. The median overall survival (OS) and progression-
free survival (PFS) was 8.9 months and 2.6 months;
comparable to the 7.1 month and 2.0 months in the ori-
ginal phase-III study [1]. Detailed data on safety and out-
comes of 55 of the 92 patients were recently published
by the authors from Japan [5].
Chemotherapy Induced Neutropenia (CIN) - at 1-month
mark
Table 1 summarizes the characteristics of patients
with chemotherapy-induced neutropenia at 1 month
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(CIN-1-month positive) and those who did not achieve
chemotherapy-induced neutropenia at 1 month (CIN-
1-month negative). A total of 69 (46.3 %) patients de-
veloped ≥ grade 2 CIN at 1 month-mark. Patients who
developed ≥ grade 2 CIN-1-month had a both longer
progression-free survival (median 3.0 months versus
2.4 months; Log-rank P-value = 0.0096; Fig. 2) as well as
overall survival (14.0 versus 5.6 months; Log-rank P-value
< 0.0001; Fig. 2). Additionally, the number of CIN-1-month
positive patients achieved disease control was 32 (49.2 %) as
compared to 28 (37.8 %) in the CIN-1-month negative
group (P-value = 0.18). There were no significant differences
in the sex, older adults, primary site (colon versus rectum)
and RAS-mutational status between the two cohorts.
Table 1 Comparison of patients with metastatic colorectal cancer who achieved chemotherapy induced neutropenia (CIN) ≥ grade
2 CTCAE (EXPOSED – CIN-1-Month positive) as compared to those who did NOT have ≥ grade 2 CIN at the 1-month mark – (Referent
– CIN-1-Month – ve) after starting treatment with TAS-102
Variable Patients with CIN-1-month N (%)
(CIN-1 month positive)
Patients without CIN-1-month N (%)
(CIN-1 month - ve)
P-value
1 Number 69 (46.3 %) 80 (53.7 %)
2 Females 29 (42.0 %) 42 (52.5 %) 0.20
3 Older Adults (Age > 65 years) 39 (56.5 %) 39 (48.8 %) 0.34
4 EAP (versus validation cohort) 33 (47.8 %) 37 (46.3 %) 0.85
5 Primary site Colon (vs. Rectal) 38 (55.1 %) 50 (62.5 %) 0.36
6 RAS-wild type 32 (46.4 %) 41 (51.3 %) 0.56
7 High Baseline CEA (> 55 ng/ml) 24 (34.7 %) 43 (53.8 %) 0.02*
8 Higher Baseline Neutrophil Count (> 4300/mm3) 19 (27.5 %) 55 (68.8 %) <0.0001**
9 Overall disease control rate (DCR) 32 (49.2 %) 28 (37.8 %) 0.18
-Partial Response (PR) -4 (6.1 %) -1 (1.3 %)
-Stable Disease (SD) -28 (43.1 %) -27 (36.5 %)
-Progressive Disease (PD) -33 (50.8 %) -46 (62.2 %)
10 Progression Free Survival (PFS) in months (95 % CI2) 3.0 (2.3–3.6) 2.4 (1.9–2.9) 0.0096*
11 Overall Survival (OS) in months (95 % CI2) 14.0 (11.2-NR1) 5.6 (4.7–8.1) <0.0001**
1NR not reached, 2CI confidence interval
*p-value < 0.05
**p-value < 0.001
Fig. 2 Kaplan-Meier curves for progression-free survival (PFS; median 3.0 months versus 2.4 months; Log-rank P-value = 0.01) as well as overall
survival (OS; median 14.0 months versus 5.6 months; Log-rank P-value < 0.0001) for patients who achieved chemotherapy induced neutropenia
(CIN) ≥ grade 2 CTCAE (red line – 69 patients (46.3 %) – CIN-1-month positive) as compared to those who did NOT have≥ grade 2 CIN at the
1-month mark (blue line – 80 patients (53.7 %) – CIN-1-month negative) after starting treatment with TAS-102
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Hazard ratios (HR) for overall survival alongside 95 %
confidence intervals (CI) were estimated through the
Cox proportional hazards model (Table 2). Separate ana-
lyses for different stratum are shown. Only CIN-1-month
(adjusted HR: 0.21; 95 % CI: 0.11–0.38: P-value < 0.0001)
and ‘Higher Baseline CEA’ (adjusted HR: 2.00; 95 % CI:
1.22–3.35: P-value 0.0062) were noted to be independent
predictors of overall survival. All P-values for interaction
were higher than 0.20. Overall survival was significantly
different between the CIN-1-month positive and CIN-1-
month negative patients in both the ‘Higher Baseline CEA’
(9.4 months versus 4.5 months; P-value 0.0006) and ‘Lower
Baseline CEA’ (median not reached versus 8.0 months;
P-value 0.0003) groups of colorectal cancer patients.
Furthermore, the CIN-1-month was noted to be a
statistically significantly predictor of overall survival
over a wide range of cutoffs (Table 2).
Discussion
Our study suggests that chemotherapy induced neutro-
penia at 1-month mark (CIN-1-month) after starting
TAS-102 appears to be a prognostic and/or predictive bio-
marker of both PFS and OS in patients with refractory
metastatic colorectal cancer. Individuals who developed
CIN-1-month had a significant improved survival (14.0
versus 5.6 months; P-value < 0.0001).
In both the previously conducted phase-II and the
recently published phase-III study, neutropenia was
the most common adverse event in patients who re-
ceived TAS-102 [1, 6]. This required at least one dose
reduction and/or a treatment interruption in up to a
third of patients [7–9]. Similar safety and efficacy was
noted in subsequent studies [5].
Although the mechanism underlying the association of
CIN-1-month and OS in patients with refractory meta-
static colorectal cancer is not entirely clear, three hy-
potheses can be postulated (Fig. 1). Firstly, one may
postulate that patients with a high tumor burden could
have a high baseline neutrophil count; making it less
likely to experience CIN-1-month. Secondly, since the
drug incorporates into the tumor, for patients with a high
tumor burden, it is possible that that the standard dosage
of the drug may not be enough to exert myelotoxicity. Fi-
nally, individuals experiencing different degrees of neutro-
penia may have different pharmacokinetics of TAS-102
and its metabolites. Our analyses, however, showed that
the CIN-1-month was still statistically significantly associ-
ated with OS after controlling for tumor burden and other
potential confounders.
Based on these observations, one can postulate that the
dosage of TAS-102 may need to be increased in patients
not experiencing any neutropenia to improve outcomes.
Conversely, one may consider increasing the interval of
chemotherapy instead of decreasing the TAS-102 dose in
the subset of patients having significant decline in their
absolute neutrophil counts without any clinical complica-
tions [10]. Prophylactic antibiotics and the use of growth
factor support with a different dosing schedule may be
other considerations, especially when considering combin-
ing this novel agent with other chemotherapy regimens
for potential future clinical trials [11].
Of note, correlation between chemotherapy induced
toxicities and favorable outcomes have been described
previously in a number of different settings [12, 13].
Whether this is purely related to pharmacokinetics of
the drug or other proposed mechanisms as outlined
above remains to be determined.
Our study, however, has several limitations. First, our
sample size was relatively small for some of the stratified
analyses as shown by wide confidence intervals. Follow
up for some of the patients in the EAP cohort is still
relatively short. The majority of the patients, however,
had already progressed on the study drug given the
highly refractory nature of the population under study.
Our observation is hypothesis generating and has a
number of strengths. First, it was based on a prospect-
ively enrolled EAP cohort as part of the expanded access
Table 2 Association between CIN-1-month and overall survival
in patients with metastatic colorectal cancer receiving TAS-102
Sample or stratum HR (95 % CI)a P-value
Overall 0.22 (0.12–0.38) < 0.0001
Strata
Men 0.15 (0.06–0.33) < 0.0001
Women 0.31 (0.13–0.67) 0.0023
Rectal 0.36 (0.15–0.78) 0.0092
Colon 0.15 (0.06–0.34) < 0.0001
RAS-mutant 0.32 (0.15–0.64) 0.001
RAS-wild type 0.14 (0.05–0.35) < 0.0001
Older adults (age > 65 years) 0.19 (0.09–0.40) < 0.0001
Younger adults (age≤ 65 years) 0.21 (0.07–0.52) 0.0003
Higher Baseline CEA (> 55 ng/ml) 0.26 (0.11–0.56) 0.0004
Lower Baseline CEA (≤ 55 ng/ml) 0.18 (0.07–0.42) < 0.0001
Higher Baseline Neutrophil Count
(> 4300/mm3)
0.25 (0.08–0.57) 0.0005
Lower Baseline Neutrophil Count
(≤ 4300/mm3)
0.27 (0.11–0.65) 0.0035
Absolute Neutrophil cutoff at 1-month
CIN-1-month (< 1000/mm3) 0.34 (0.16–0.66) 0.0008
CIN-1-month (< 1500/mm3) 0.22 (0.12–0.38) < 0.0001
CIN-1-month (< 2000/mm3) 0.28 (0.17–0.47) < 0.0001
CIN-1-month (< 2500/mm3) 0.25 (0.16–0.42) < 0.0001
CIN-1-month (< 3000/mm3) 0.26 (0.16–0.43) < 0.0001
aHR for overall survival was calculated through Cox proportional
hazards models
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clinical trial with similar cohort of patients with refrac-
tory colorectal cancer. Second, we were able to corrob-
orate the observations in an independent cohort of
patients from a different center as well as a different
country. Third, analyses were stratified for several
known prognostic factors and potential confounding
effects were explored. Validation of our findings in an
independent population cohort is the strength of this
analysis and provides a readily available potentially pre-
dictive as well as prognostic biomarker (CIN-1-month)
for patients with metastatic colorectal cancer.
Conclusions
Neutropenia after starting TAS-102 was associated with
better prognosis in patients with refractory mCRC. Our
findings are clinically relevant and have led to re-
analyses of both the initial randomized phase-II (Study
J003-10040030) and phase-III (RECOURSE trial) studies
of TAS-102 versus placebo, and similar results were
seen. These findings are important since it can be postu-
lated that the dosage of TAS-102 potentially may need
to be increased to achieve better outcomes in patients
not experiencing any neutropenia. Further pharmaco-
logic investigations should help elucidate these issues
and help validate the potential utility of CIN-1-month as
a prognostic and/or predictive biomarker of TAS-102
for patients with refractory mCRC.
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